China’s AI Drug Discovery Reaches a Clinical Milestone — and a Global Inflection Point
Insilico Medicine, the Hong Kong and China-based AI drug discovery company, has administered the first dose to a human patient in a Phase I clinical trial of ISM8969, a small-molecule NLRP3 inhibitor discovered entirely through artificial intelligence.